{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:56:32Z","timestamp":1790355392548,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI148632"],"award-info":[{"award-number":["R01 AI148632"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Due to the limited size of viral genomes, most viral proteins are multifunctional; yet most direct-acting antivirals are designed as single-function inhibitors. The dengue virus (DENV) capsid protein serves as a building block for new virions while also interacting with multiple host factors to remodel the cellular environment. Using established capsid inhibitor ST148 as a targeting ligand, we develop a DENV capsid degrader, RPG-01-132, that exhibits a broadened spectrum of activity against the four DENV serotypes and an ST148-resistant mutant virus. Using multiple approaches, we show that RPG-01-132\u2019s sub-micromolar antiviral activity is due to CRL4\n                    <jats:sup>CRBN<\/jats:sup>\n                    -dependent degradation of capsid and that this mechanism disrupts capsid-related pathways required for productive infection, including infectious virus output and capsid-mediated antagonism of the interferon response. This pharmacology is well-differentiated from ST148, which interferes with assembly of new virions, but has no demonstrated effect on the capsid\u2019s nonstructural functions. These findings demonstrate that targeted protein degradation can thus enable antiviral pharmacology not observed with conventional antiviral inhibitors and\u00a0that is\u00a0resilient to point mutations that reduce inhibitor potency.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-69263-w","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:55:13Z","timestamp":1770728113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Degraders of the dengue virus capsid protein exhibit differentiated pharmacology relative to capsid inhibitors"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5440-990X","authenticated-orcid":false,"given":"Antara","family":"Chakravarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3908-7946","authenticated-orcid":false,"given":"Lu-Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7113-007X","authenticated-orcid":false,"given":"Ryan P.","family":"Golden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-8011","authenticated-orcid":false,"given":"Zhengnian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-5106","authenticated-orcid":false,"given":"Katherine A.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oshri","family":"Afanzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yupeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-6306","authenticated-orcid":false,"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7403","authenticated-orcid":false,"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-2557","authenticated-orcid":false,"given":"Priscilla L.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"69263_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes, M., Langley, D. R. & Crews, C. M. PROTAC targeted protein degraders: the past is prologue. Nat. Rev. Drug Discov. 21, 181\u2013200 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"69263_CR2","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1039\/D2CS00193D","volume":"51","author":"K Li","year":"2022","unstructured":"Li, K. & Crews, C. M. PROTACs: past, present and future. Chem. Soc. Rev. 51, 5214\u20135236 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"69263_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611\u2013617 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"69263_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1021\/acs.jmedchem.7b00635","volume":"61","author":"AP Crew","year":"2018","unstructured":"Crew, A. P. et al. Identification and characterization of Von Hippel-Lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1. J. Med. Chem. 61, 583\u2013598 (2018).","journal-title":"J. Med. Chem."},{"key":"69263_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere, M. et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 10, 3468 (2019).","journal-title":"Nat. Commun."},{"key":"69263_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49161-9","volume":"15","author":"HY Liu","year":"2024","unstructured":"Liu, H. Y. et al. Broad-spectrum activity against mosquito-borne flaviviruses achieved by a targeted protein degradation mechanism. Nat. Commun. 15, 5179 (2024).","journal-title":"Nat. Commun."},{"key":"69263_CR7","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.chembiol.2024.02.004","volume":"31","author":"LA Emert-Sedlak","year":"2024","unstructured":"Emert-Sedlak, L. A. et al. PROTAC-mediated degradation of HIV-1 Nef efficiently restores cell-surface CD4 and MHC-I expression and blocks HIV-1 replication. Cell Chem. Biol. 31, 658\u2013668 e614 (2024).","journal-title":"Cell Chem. Biol."},{"key":"69263_CR8","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1021\/acs.jmedchem.3c02416","volume":"67","author":"YR Alugubelli","year":"2024","unstructured":"Alugubelli, Y. R. et al. Discovery of first-in-class PROTAC degraders of SARS-CoV-2 main protease. J. Med Chem. 67, 6495\u20136507 (2024).","journal-title":"J. Med Chem."},{"key":"69263_CR9","doi-asserted-by":"publisher","first-page":"116202","DOI":"10.1016\/j.ejmech.2024.116202","volume":"268","author":"J Desantis","year":"2024","unstructured":"Desantis, J. et al. Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity. Eur. J. Med. Chem. 268, 116202 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"69263_CR10","doi-asserted-by":"publisher","first-page":"7154","DOI":"10.1021\/acs.jmedchem.1c02013","volume":"65","author":"H Li","year":"2022","unstructured":"Li, H. et al. Discovery of pentacyclic triterpenoid PROTACs as a class of effective hemagglutinin protein degraders. J. Med. Chem. 65, 7154\u20137169 (2022).","journal-title":"J. Med. Chem."},{"key":"69263_CR11","doi-asserted-by":"publisher","first-page":"100030","DOI":"10.1016\/j.cellin.2022.100030","volume":"1","author":"Z Xu","year":"2022","unstructured":"Xu, Z. et al. Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus. Cell Insight 1, 100030 (2022).","journal-title":"Cell Insight"},{"key":"69263_CR12","doi-asserted-by":"publisher","unstructured":"Liu, Y. Y. et al. Harnessing multiplexed proteolysis-targeting chimera for comprehensive influenza A virus targeting. J. Am. Chem. Soc. https:\/\/doi.org\/10.1021\/jacs.5c09384 (2025).","DOI":"10.1021\/jacs.5c09384"},{"key":"69263_CR13","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.apsb.2025.02.033","volume":"15","author":"S Xu","year":"2025","unstructured":"Xu, S. et al. Discovery and mechanism verification of first-in-class hydrophobic tagging-based degraders of HBV core protein. Acta Pharm. Sin. B 15, 2170\u20132196 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"69263_CR14","doi-asserted-by":"publisher","unstructured":"Veeck, C., Laube, L., Werner, A., Diederich, W. & Becker, S. Discovery of an antiviral PROTAC targeting the SARS-CoV-2 main protease using an allosteric warhead. Preprint athttps:\/\/doi.org\/10.1101\/2025.05.03.652023 (2025).","DOI":"10.1101\/2025.05.03.652023"},{"key":"69263_CR15","doi-asserted-by":"publisher","first-page":"8791","DOI":"10.1021\/acs.jmedchem.4c00131","volume":"67","author":"X Ma","year":"2024","unstructured":"Ma, X. et al. Novel acyl thiourea-based hydrophobic tagging degraders exert potent anti-influenza activity through two distinct endonuclease polymerase acidic-targeted degradation pathways. J. Med Chem. 67, 8791\u20138816 (2024).","journal-title":"J. Med Chem."},{"key":"69263_CR16","doi-asserted-by":"publisher","first-page":"129880","DOI":"10.1016\/j.bmcl.2024.129880","volume":"111","author":"D Luo","year":"2024","unstructured":"Luo, D. et al. Discovery of L15 as a novel Vif PROTAC degrader with antiviral activity against HIV-1. Bioorg. Med Chem. Lett. 111, 129880 (2024).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"69263_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56317-8","volume":"16","author":"LS Newton","year":"2025","unstructured":"Newton, L. S. et al. Macrocycle-based PROTACs selectively degrade cyclophilin A and inhibit HIV-1 and HCV. Nat. Commun. 16, 1484 (2025).","journal-title":"Nat. Commun."},{"key":"69263_CR18","doi-asserted-by":"publisher","unstructured":"Hahn, F. et al. Development of a PROTAC-based targeting strategy provides a mechanistically unique mode of anti-cytomegalovirus activity. Int. J. Mol. Sci. 22. https:\/\/doi.org\/10.3390\/ijms222312858 (2021).","DOI":"10.3390\/ijms222312858"},{"key":"69263_CR19","doi-asserted-by":"publisher","unstructured":"Echavarria-Consuegra, L. & Goodfellow, I. Proof of concept: targeted protein degradation of the stress granules component G3BP1 as an antiviral strategy against norovirus infection. Antimicrob Agents Chemother. e0111825 https:\/\/doi.org\/10.1128\/aac.01118-25 (2026). Epub ahead of print.","DOI":"10.1128\/aac.01118-25"},{"key":"69263_CR20","doi-asserted-by":"publisher","first-page":"123401","DOI":"10.1016\/j.lfs.2025.123401","volume":"363","author":"J Jungwirth","year":"2025","unstructured":"Jungwirth, J. et al. Pharmacologically induced proteolysis of histone deacetylase-6 attenuates influenza virus replication despite limited anti-tumor effects. Life Sci. 363, 123401 (2025).","journal-title":"Life Sci."},{"key":"69263_CR21","doi-asserted-by":"publisher","first-page":"129680","DOI":"10.1016\/j.bmcl.2024.129680","volume":"102","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. \u201cPROTAC\u201d modified dihydroquinolizinones (DHQs) that cause degradation of PAPD-5 and inhibition of hepatitis A virus and hepatitis B virus, in vitro. Bioorg. Med Chem. Lett. 102, 129680 (2024).","journal-title":"Bioorg. Med Chem. Lett."},{"key":"69263_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.cellsig.2007.12.018","volume":"20","author":"MD Urbanowski","year":"2008","unstructured":"Urbanowski, M. D., Ilkow, C. S. & Hobman, T. C. Modulation of signaling pathways by RNA virus capsid proteins. Cell Signal 20, 1227\u20131236 (2008).","journal-title":"Cell Signal"},{"key":"69263_CR23","doi-asserted-by":"publisher","unstructured":"Airo, A. M. et al. Flavivirus capsid proteins inhibit the interferon response. Viruses 14. https:\/\/doi.org\/10.3390\/v14050968 (2022).","DOI":"10.3390\/v14050968"},{"key":"69263_CR24","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.stem.2020.07.012","volume":"27","author":"J Zeng","year":"2020","unstructured":"Zeng, J. et al. The Zika virus capsid disrupts corticogenesis by suppressing dicer activity and miRNA biogenesis. Cell Stem Cell 27, 618\u2013632 e619 (2020).","journal-title":"Cell Stem Cell"},{"key":"69263_CR25","doi-asserted-by":"publisher","unstructured":"Farelo, M. A. et al. Dengue and Zika virus capsid proteins contain a common PEX19-binding motif. Viruses 14. https:\/\/doi.org\/10.3390\/v14020253 (2022).","DOI":"10.3390\/v14020253"},{"key":"69263_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","volume":"584","author":"JO Link","year":"2020","unstructured":"Link, J. O. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature 584, 614\u2013618 (2020).","journal-title":"Nature"},{"key":"69263_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1126\/science.abb4808","volume":"370","author":"SM Bester","year":"2020","unstructured":"Bester, S. M. et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science 370, 360\u2013364 (2020).","journal-title":"Science"},{"key":"69263_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","volume":"159","author":"F Zoulim","year":"2020","unstructured":"Zoulim, F. et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology 159, 521\u2013533 e529 (2020).","journal-title":"Gastroenterology"},{"key":"69263_CR29","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1128\/AAC.43.9.2109","volume":"43","author":"DC Pevear","year":"1999","unstructured":"Pevear, D. C., Tull, T. M., Seipel, M. E. & Groarke, J. M. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43, 2109\u20132115 (1999).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69263_CR30","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1128\/AAC.03328-14","volume":"58","author":"A Tijsma","year":"2014","unstructured":"Tijsma, A. et al. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob. Agents Chemother. 58, 6990\u20136992 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69263_CR31","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1056\/NEJMe2314240","volume":"390","author":"SB Halstead","year":"2024","unstructured":"Halstead, S. B. Three dengue vaccines\u2014what now? N. Engl. J. Med 390, 464\u2013465 (2024).","journal-title":"N. Engl. J. Med"},{"key":"69263_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-virology-110615-042334","volume":"3","author":"LA Byk","year":"2016","unstructured":"Byk, L. A. & Gamarnik, A. V. Properties and functions of the dengue virus capsid protein. Annu Rev. Virol. 3, 263\u2013281 (2016).","journal-title":"Annu Rev. Virol."},{"key":"69263_CR33","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1073\/pnas.0305892101","volume":"101","author":"L Ma","year":"2004","unstructured":"Ma, L., Jones, C. T., Groesch, T. D., Kuhn, R. J. & Post, C. B. Solution structure of dengue virus capsid protein reveals another fold. Proc. Natl. Acad. Sci. USA 101, 3414\u20133419 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69263_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-03854-z","volume":"11","author":"I Sallaberry","year":"2021","unstructured":"Sallaberry, I. et al. In vivo pair correlation microscopy reveals dengue virus capsid protein nucleocytoplasmic bidirectional movement in mammalian infected cells. Sci. Rep. 11, 24415 (2021).","journal-title":"Sci. Rep."},{"key":"69263_CR35","doi-asserted-by":"publisher","first-page":"e0264643","DOI":"10.1371\/journal.pone.0264643","volume":"17","author":"NC Mebus-Antunes","year":"2022","unstructured":"Mebus-Antunes, N. C. et al. The interaction of dengue virus capsid protein with negatively charged interfaces drives the in vitro assembly of nucleocapsid-like particles. PLoS One 17, e0264643 (2022).","journal-title":"PLoS One"},{"key":"69263_CR36","doi-asserted-by":"publisher","first-page":"101059","DOI":"10.1016\/j.jbc.2021.101059","volume":"297","author":"EE Ambroggio","year":"2021","unstructured":"Ambroggio, E. E., Costa Navarro, G. S., Perez Socas, L. B., Bagatolli, L. A. & Gamarnik, A. V. Dengue and Zika virus capsid proteins bind to membranes and self-assemble into liquid droplets with nucleic acids. J. Biol. Chem. 297, 101059 (2021).","journal-title":"J. Biol. Chem."},{"key":"69263_CR37","doi-asserted-by":"publisher","first-page":"13094","DOI":"10.1128\/JVI.00704-13","volume":"87","author":"CA Balinsky","year":"2013","unstructured":"Balinsky, C. A. et al. Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles. J. Virol. 87, 13094\u201313106 (2013).","journal-title":"J. Virol."},{"key":"69263_CR38","doi-asserted-by":"publisher","first-page":"e24365","DOI":"10.1371\/journal.pone.0024365","volume":"6","author":"TM Colpitts","year":"2011","unstructured":"Colpitts, T. M., Barthel, S., Wang, P. & Fikrig, E. Dengue virus capsid protein binds core histones and inhibits nucleosome formation in human liver cells. PLoS One 6, e24365 (2011).","journal-title":"PLoS One"},{"key":"69263_CR39","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3389\/fcimb.2017.00542","volume":"7","author":"R Kumar","year":"2017","unstructured":"Kumar, R., Singh, N., Abdin, M. Z., Patel, A. H. & Medigeshi, G. R. Dengue virus capsid Interacts with DDX3X-A potential mechanism for suppression of antiviral functions in dengue infection. Front. Cell Infect. Microbiol. 7, 542 (2017).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"69263_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1128\/AAC.01429-12","volume":"57","author":"CM Byrd","year":"2013","unstructured":"Byrd, C. M. et al. A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob. Agents Chemother. 57, 15\u201325 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"69263_CR41","doi-asserted-by":"publisher","first-page":"17992","DOI":"10.1073\/pnas.2003056117","volume":"117","author":"H Xia","year":"2020","unstructured":"Xia, H. et al. A cocrystal structure of dengue capsid protein in complex of inhibitor. Proc. Natl. Acad. Sci. USA 117, 17992\u201318001 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69263_CR42","doi-asserted-by":"publisher","first-page":"18022","DOI":"10.1021\/acs.jmedchem.4c01305","volume":"67","author":"X Zheng","year":"2024","unstructured":"Zheng, X. et al. Discovery of KT-474 horizontal line a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases. J. Med Chem. 67, 18022\u201318037 (2024).","journal-title":"J. Med Chem."},{"key":"69263_CR43","doi-asserted-by":"publisher","first-page":"21937","DOI":"10.1021\/jacs.3c06622","volume":"145","author":"RC Sarott","year":"2023","unstructured":"Sarott, R. C. et al. Chemical specification of E3 ubiquitin ligase engagement by cysteine-reactive chemistry. J. Am. Chem. Soc. 145, 21937\u201321944 (2023).","journal-title":"J. Am. Chem. Soc."},{"key":"69263_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.virol.2008.08.021","volume":"381","author":"C Ansarah-Sobrinho","year":"2008","unstructured":"Ansarah-Sobrinho, C., Nelson, S., Jost, C. A., Whitehead, S. S. & Pierson, T. C. Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology 381, 67\u201374 (2008).","journal-title":"Virology"},{"key":"69263_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"69263_CR46","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1021\/acschembio.7b00969","volume":"13","author":"M Ishoey","year":"2018","unstructured":"Ishoey, M. et al. Translation termination factor GSPT1 is a phenotypically relevant off-target of heterobifunctional phthalimide degraders. ACS Chem. Biol. 13, 553\u2013560 (2018).","journal-title":"ACS Chem. Biol."},{"key":"69263_CR47","doi-asserted-by":"publisher","first-page":"110544","DOI":"10.1016\/j.celrep.2022.110544","volume":"38","author":"J Fang","year":"2022","unstructured":"Fang, J. et al. Functional interactomes of the Ebola virus polymerase identified by proximity proteomics in the context of viral replication. Cell Rep. 38, 110544 (2022).","journal-title":"Cell Rep."},{"key":"69263_CR48","doi-asserted-by":"publisher","first-page":"e2201208119","DOI":"10.1073\/pnas.2201208119","volume":"119","author":"J Fang","year":"2022","unstructured":"Fang, J. et al. Proximity interactome analysis of Lassa polymerase reveals eRF3a\/GSPT1 as a druggable target for host-directed antivirals. Proc. Natl. Acad. Sci. USA 119, e2201208119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69263_CR49","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.chom.2023.05.030","volume":"31","author":"N Zhao","year":"2023","unstructured":"Zhao, N. et al. Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics. Cell Host Microbe 31, 1154\u20131169 e1110 (2023).","journal-title":"Cell Host Microbe"},{"key":"69263_CR50","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood.2020008676","volume":"137","author":"C Surka","year":"2021","unstructured":"Surka, C. et al. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells. Blood 137, 661\u2013677 (2021).","journal-title":"Blood"},{"key":"69263_CR51","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1021\/acs.jmedchem.0c01313","volume":"64","author":"G Nishiguchi","year":"2021","unstructured":"Nishiguchi, G. et al. Identification of potent, selective, and orally bioavailable small-molecule GSPT1\/2 degraders from a focused library of cereblon modulators. J. Med Chem. 64, 7296\u20137311 (2021).","journal-title":"J. Med Chem."},{"key":"69263_CR52","doi-asserted-by":"publisher","first-page":"11540","DOI":"10.1128\/JVI.01745-14","volume":"88","author":"P Scaturro","year":"2014","unstructured":"Scaturro, P. et al. Characterization of the mode of action of a potent dengue virus capsid inhibitor. J. Virol. 88, 11540\u201311555 (2014).","journal-title":"J. Virol."},{"key":"69263_CR53","doi-asserted-by":"publisher","first-page":"14333","DOI":"10.1073\/pnas.2335168100","volume":"100","author":"JL Munoz-Jordan","year":"2003","unstructured":"Munoz-Jordan, J. L., Sanchez-Burgos, G. G., Laurent-Rolle, M. & Garcia-Sastre, A. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. USA 100, 14333\u201314338 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69263_CR54","doi-asserted-by":"publisher","first-page":"9760","DOI":"10.1128\/JVI.01051-10","volume":"84","author":"JR Rodriguez-Madoz","year":"2010","unstructured":"Rodriguez-Madoz, J. R. et al. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J. Virol. 84, 9760\u20139774 (2010).","journal-title":"J. Virol."},{"key":"69263_CR55","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/605847","volume":"200","author":"M Mazzon","year":"2009","unstructured":"Mazzon, M., Jones, M., Davidson, A., Chain, B. & Jacobs, M. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 200, 1261\u20131270 (2009).","journal-title":"J. Infect. Dis."},{"key":"69263_CR56","doi-asserted-by":"publisher","first-page":"6210","DOI":"10.1039\/D2CS00339B","volume":"51","author":"KM Riching","year":"2022","unstructured":"Riching, K. M., Caine, E. A., Urh, M. & Daniels, D. L. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation. Chem. Soc. Rev. 51, 6210\u20136221 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"69263_CR57","doi-asserted-by":"publisher","first-page":"14129","DOI":"10.1021\/acs.jmedchem.5c01818","volume":"68","author":"Z Ma","year":"2025","unstructured":"Ma, Z. & Zhou, J. NDA submission of vepdegestrant (ARV-471) to U.S. FDA: the beginning of a new era of PROTAC degraders. J. Med Chem. 68, 14129\u201314136 (2025).","journal-title":"J. Med Chem."},{"key":"69263_CR58","doi-asserted-by":"publisher","first-page":"872729","DOI":"10.3389\/fcell.2022.872729","volume":"10","author":"MR Burke","year":"2022","unstructured":"Burke, M. R., Smith, A. R. & Zheng, G. Overcoming cancer drug resistance utilizing PROTAC technology. Front Cell Dev. Biol. 10, 872729 (2022).","journal-title":"Front Cell Dev. Biol."},{"key":"69263_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67\u201377.e63 (2018).","journal-title":"Cell Chem. Biol."},{"key":"69263_CR60","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1182\/blood-2018-07-862953","volume":"133","author":"D Dobrovolsky","year":"2019","unstructured":"Dobrovolsky, D. et al. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood 133, 952\u2013961 (2019).","journal-title":"Blood"},{"key":"69263_CR61","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57, 3564\u20133575 (2018).","journal-title":"Biochemistry"},{"key":"69263_CR62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s43856-025-00863-1","volume":"5","author":"B Pan","year":"2025","unstructured":"Pan, B. et al. Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus. Commun. Med (Lond.) 5, 140 (2025).","journal-title":"Commun. Med (Lond.)"},{"key":"69263_CR63","doi-asserted-by":"publisher","first-page":"116629","DOI":"10.1016\/j.ejmech.2024.116629","volume":"275","author":"S Cheng","year":"2024","unstructured":"Cheng, S. et al. Development of novel antiviral agents that induce the degradation of the main protease of human-infecting coronaviruses. Eur. J. Med Chem. 275, 116629 (2024).","journal-title":"Eur. J. Med Chem."},{"key":"69263_CR64","doi-asserted-by":"publisher","first-page":"115793","DOI":"10.1016\/j.ejmech.2023.115793","volume":"261","author":"S Zeng","year":"2023","unstructured":"Zeng, S. et al. Current advances and development strategies of orally bioavailable PROTACs. Eur. J. Med. Chem. 261, 115793 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"69263_CR65","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376\u20131381 (2015).","journal-title":"Science"},{"key":"69263_CR66","doi-asserted-by":"publisher","unstructured":"Afanzar, O. MATLAB Code to Analyze Microscopy Data. https:\/\/doi.org\/10.5281\/zenodo.18259090 (2025).","DOI":"10.5281\/zenodo.18259090"},{"key":"69263_CR67","doi-asserted-by":"publisher","unstructured":"Donovan, K. A. et al. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife 7. https:\/\/doi.org\/10.7554\/eLife.38430 (2018).","DOI":"10.7554\/eLife.38430"},{"key":"69263_CR68","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"69263_CR69","doi-asserted-by":"crossref","unstructured":"Baek, K. et al. Unveiling the hidden interactome of CRBN molecular glues with chemoproteomics. Nat. Commun. 16, 6831 (2025).","DOI":"10.1038\/s41467-025-62099-w"},{"key":"69263_CR70","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69263-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69263-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:03:22Z","timestamp":1773932602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69263-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69263"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69263-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.L.Y. is a founder and science advisory board member (SAB) of Viraccio Therapeutics. N.S.G. is a founder, science advisory board member (SAB), and equity holder in Syros, C4, Allorion, Lighthorse, Inception, Matchpoint, Shenandoah (board member), Larkspur (board member), and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. K.A.D. receives or has received consulting fees from Neomorph Inc. and Kronos Bio. E.S.F. is a founder, SAB and equity holder in Neomorph (board member), Civetta, Anvia (board member), Proximity, and Stelexis; consultant\/SAB and equity holder in Ajax, Avilar, and Photys; equity holder in Lighthorse and CPD4 (board member). The Fischer lab has received or continues to receive research funding from Novartis, Astellas, Ajax, Deerfield, Springworks, and Interline. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2594"}}